MindMap Gallery Roquefort Therapeutics ROQ
This detailed mind map of "Roquefort Therapeutics ROQ" delves into key areas such as the company's foundation, management structure, biotech products, and medical research. Each section is further categorized into subtopics like company overview, R&D pipeline, market analysis, partners, management team, etc., presenting a comprehensive view of the company and its growth potential.
Edited at 2022-10-23 12:02:11Explore the facets of "Hemogenyx Hemo Strategies" in this mind map. Key branches, including "LES MAIN," "Biotech," and "Immunotherapies for Blood Cancers," delineate pivotal aspects of the company's strategic landscape. Dive into details regarding the LES MAIN initiative, the biotech sector involvement, and the focus on immunotherapies for combating blood cancers. Tailored for stakeholders, investors, and industry enthusiasts
Hellenic Dynamics encapsulates the intricate interplay of historical, cultural, and philosophical elements that have defined the civilization of Ancient Greece. This mind map aims to visually organize key aspects within Hellenic Dynamics, offering a comprehensive overview for students, researchers, and individuals interested in delving into the richness of Ancient Greek civilization.
This detailed mind map of "Marula Mining MARU" mainly introduces "News", "Media", and "Kinusi,Bagamoyo", etc. Under "News", it details the news and events of Marula Mining; under "Media", it details the media relations and reports of Marula Mining; under "Kinusi,Bagamoyo", it details the geographical location and community relations of Marula Mining.
Explore the facets of "Hemogenyx Hemo Strategies" in this mind map. Key branches, including "LES MAIN," "Biotech," and "Immunotherapies for Blood Cancers," delineate pivotal aspects of the company's strategic landscape. Dive into details regarding the LES MAIN initiative, the biotech sector involvement, and the focus on immunotherapies for combating blood cancers. Tailored for stakeholders, investors, and industry enthusiasts
Hellenic Dynamics encapsulates the intricate interplay of historical, cultural, and philosophical elements that have defined the civilization of Ancient Greece. This mind map aims to visually organize key aspects within Hellenic Dynamics, offering a comprehensive overview for students, researchers, and individuals interested in delving into the richness of Ancient Greek civilization.
This detailed mind map of "Marula Mining MARU" mainly introduces "News", "Media", and "Kinusi,Bagamoyo", etc. Under "News", it details the news and events of Marula Mining; under "Media", it details the media relations and reports of Marula Mining; under "Kinusi,Bagamoyo", it details the geographical location and community relations of Marula Mining.
Roquefort Therapeutics ROQ
Biotech
Pre-Clinical Oncology
LSE Main Market
Midkine Inhibiting RNA Drugs
What is Midkine?: Growth Factor protein expressed in embryo to aid development of body, then switches off at birth to almost undetectable levels. Switches on again in certain conditions - Cancer / AutoImmunes Diseases / Chronic Inflammation - including Covid. Inhibition of Midkine leads to a significant improvement in body's response to these conditions. Midkine disrupts tumours immune response leading to metastasis (spread), and promtes tumour survival.
Largest Global Patent Portfolio
Very positive In-vitro results from lead drug candidates. Progressing to Mouse(in-vivo) studies Patent Protected.
Midkine Antibody Program
Midkine Oligo Program
STAT-6 mIRNA
MK cellular Therapeutics
Promising approach - Promotes bodies own Natural Killer (NK) Cells.
Early Value Creation
Plan is to do the Preclinical work then sell / partner to Big Pharma Thus avoiding Expensive and Risky clinical trials 'Capital Light' Model? - ref Poolbeg Pharma (POLB) Multi $ Billion Potential - as evidenced by Mallinckrodt / Slience $2.1 Billion, and Genetech / Skyhawk $2.0 Billion.
Media
Company Presentation
Fundamentals
Main Market + OTCQP. Shares 129M for MCap of £9.8M as at mid Oct '22. Board has significant 'Skin in the game' with recent multiple Director Buys. Thinly Traded - Av Daily Volume 157K September 2022: Placing raises £1M @14p - Stephen Ward Buys 20 000 shares. Leaving £2.49 Cash. ?Cashburn, but state fully funded
For
Relevantly Experienced BOD - Well Connected? Area of Need - Multi $Billion Potential 'Capital Light' Model Preclinical = Reduced Risk Significant 'Skin in the Game' Low MCap Very promising 'Pipeline' Seems like an obvious Buyout Target at some point
Against
Finance - Funding -Cash Burn - Dilution Competition: Medikine: USA: Similar Stage Lightly traded at present / Poor technicals
Management
Large & Highly experienced Board, with what seems like plenty of relevant experience in Biotech startups / Gene Therapy / Company development
Ajan Reginald CEO
CEO - 30Y experience in Biotech / Drug Development & Commercialization. Worked with Roche / Novacyt SA / Celexir. Worked with Prof Martin Evans on development and commercialization of Celexirs novel cardiac drug. Celexir valued at £220M
Prof Martin Evans
Group Chief Scientific Officer. 2007 Nobel Prizefor Medicine - Discovery of Embryonic Stem cells and DNA recombination in mammals. Highly respected academic - worldwide contacts
Dr Graham Robertson
Vice President of Drug Discovery. PhD in Molecular Virology. Gene regulation / Nuclear architecture / Transgenic mice / Liver fibosis - NASH / Gene regulation - drug metabolism / Explored link between chronic inflammation and metabolic disruption causing cachexia.
Prof Trevor Jones
Strategic & Scientific Advisor: 45Y in Biotech & Pharmaceuticals Prev Director for Research & Development @ Wellcome Foundation. Non-Exec Director @Allergan Experience in Drug development and commercialization. Served as government advisor during Covid pandemic.
Stephen West EC
Chartered Accountant with 30Y experience in Resource sector / Investment Banking. Extensive experience with Growth Companies / IPOs / Corporate Finance / Fundraising. Currently also Non-Exec of EnergyPathways.
Dr Darren Disley
Non-Exec Director: Renowned scientist, entrepeneur , Angel Investor. Partaken in 40 startups in Life Science, Technology and Social enterprises. CEO of Horizon Discovery for 11Y - From start-up to $113M IPO to become a world leader in Gene Editing / Modulation.